Sectionary Analysis Of Thyroid Function Tests, Vitamin B12 And Folic Acid Levels In Patients With Type 2 Diabetes Mellitus, Hypertension, Chronic Renal Disease And Gastroesophageal Reflux Disease

Öz

The most common diseases presenting to the internal medicine outpatient clinic are type 2 diabetes mellitus, hypertension, chronic kidney disease and gastroesophageal reflux disease. Thyroid function tests, vitamin B12 and folic acid levels were compared in these diseases. Within the scope of the study, 91 patients were included in the study. Cases with type 2 diabetes mellitus, hypertension, chronic kidney disease and gastroesophageal reflux disease as chronic diseases were examined in the study. In this context, besides demographic data and routine biochemical data, TSH, fT4, fT4, vitamin B12 and folic acid levels were also scanned retrospectively from patient files. The mean age of the 91 patients included in the study was 61.29 ± 14.23 and was not statistically different between the groups. The FT3 level was found to be the highest in the first group compared to the other groups, but it was not statistically significant (p=0.863). The highest FT4 level was detected in group 4, but it was not statistically significant (p=0.839). TSH value was found to be the highest in the gastroesophageal reflux disease group and was not statistically significant when compared to other groups (p=0.898). The comparison of folic acid and vitamin B12 levels between the groups was not statistically significant (p=0.605). Spearmens’s correlation analysis revealed folic acid was significantly positive correlated with folic acid (rho=0.797, p=0.001). TSH levels were not significantly corelated with fT3, fT4, folic acid and vitamin B12 (rho=0.015, p=0.891; rho= -0.177, p=0.093; rho=0.011, p=0.916; rho=0.153, p=0.147). This study demonstrated that serum TSH, ft3, ft4, vitamin b12 and folic acid levels were found similar in all groups. On the other hand, significant difference ws not found between groups in term of TSH,fT3, fT4, vitamin B12 and folic acid.

Anahtar Kelimeler

• Type 2 diabetes mellitus
• hypertension
• chronic renal diseas
• gastroesophageal reflux disease

Kaynakça

1. 1. Chiang JL, Kirkman MS, Laffel LM, et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014; 37:2034.
2. 2. Purnell JQ, Dev RK, Steffes MW, et al. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 2003; 52:2623.
3. 3. Muntner P, Carey RM, Gidding S, et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation 2018; 137:109.
4. 4. Yoon SS, Gu Q, Nwankwo T, et al. Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension 2015; 65:54.
5. 5. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305.
6. 6. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199.
7. 7. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043.
8. 8. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26:60.

9. 9. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398:957.
10. 10. Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011) 2013; 3:19.
11. 11. P. Sharma, S. Wani, Y. Romero, D. Johnson, and F. Hamilton, “Racial and geographic issues in gastroesophageal reflux disease,” American Journal of Gastroenterology, vol. 103, no. 11, pp. 2669–2680, 2008.
12. 12. I. Wiklund, “Review of the quality of life and burden of illness in gastroesophageal reflux disease,” Digestive Diseases, vol. 22, no. 2, pp. 108–114, 2004.
13. 13. E. M. Quigley, “Review article: gastric emptying in functional gastrointestinal disorders,” Alimentary Pharmacology and Therapeutics, vol. 20, supplement 7, pp. 56–60, 2004.
14. 14. G. Shi, S. Bruley des Varannes, C. Scarpignato, M. Le Rhun, and J.-P. Galmiche, “Reflux related symptoms in patients with normal oesophageal exposure to acid,” Gut, vol. 37, no. 4, pp. 457–464, 1995. Yıldız et al.
15. 15. H. Noto, T. Mitsuhashi, S. Ishibashi, and S. Kimura, “Hyperthyroidism presenting as dysphagia,” Internal Medicine, vol. 39, no. 6, pp. 472–473, 2000.
16. 16. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000; 30: 29–33
17. 17. Lachner C, Steinle NI, Regenold WT. The neuropsychiatry of vitamin B12 deficiency in elderly patients. J Neuropsychiatry Clin Neurosci 2012; 24: 5–15.
18. 18. Kapadia C. Cobalamin (vitamin B12) Deficiency: Is it a Problem for Our Aging Population and Is the Problem Compounded by Drugs That Inhibit Gastric Acid Secretion? New Haven (CT): Yale University School of Medicine; 2000; 4–6.
19. 19. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012; 28: 615–20.
20. 20. Ianiro, G.; Mangiola, F.; Di Rienzo, T.A.; Bibbò, S.; Franceschi, F.; Greco, A.V.; Gasbarrini, A. Levothyroxine absorption in health and disease, and new therapeutic perspectives. Eur. Rev. Med. Pharmacol. Sci. 2014, 18, 451–456.
21. 21. Sachmechi, I.; Reich, D.M.; Aninyei, M.; Wibowo, F.; Gupta, G.; Kim, P.J. Effect of proton pump inhibitors on serum thyroidstimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr. Pract. 2007, 13, 345–349. [CrossRef]
22. 22. Irving, S.A.; Vadiveloo, T.; Leese, G.P. Drugs that interact with levothyroxine: An observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). Clin. Endocrinol. 2015, 82, 136–141.
23. 23. Pa´sko, P.; Wołtosz, A.; Zwoli ´nska-Wcisło, M.; Zachwieja, Z. Influence of proton pump inhibitors on calcium and iron homeostasis. Bromatol. Chem. Toksykol. 2015, 48, 484–489.
24. 24. Dietrich, J.W.; Boehm, B.O. Thyroxine in goiter, H. pylori infection, and gastritis. N. Engl. J. Med. 2006, 355, 1177
25. 25. Ananthakrishnan, S.; Braverman, L.E.; Levin, R.M.; Magnani, B.; Pearce, E.N. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid 2008, 18, 493–498.